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ment as well as anginal pains. Rate of arrhythmia at discharge
was minimal in streptokinase group. Alteplase required much
more costs than streptokinase or treatment without thrombolyt-
ical therapy. ICER was 252,454.31 rubles ($7889.20) per
absence of heart failure at discharge for alteplase vs streptoki-
nase, and 166,720.5 rubles ($5210.02) for alteplase vs treatment
without thrombolytical therapy. Still streptokinase was more
cost-effective vs treatment without thrombolytical therapy: ICER
was 4038.76 rubles ($126.21) per absence of heart failure at dis-
charge. CONCLUSION: Alteplase is less cost-effective throm-
bolytical strategy for MI than streptokinase in spite of higher
effectiveness.
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OBJECTIVES: We assessed the long-term cost-effectiveness of
the use of clopidogrel on top of standard therapy (including
aspirin) in comparison with ASA only in patients undergoing
percutaneous coronary interventions in Sweden. METHODS: A
Markov model was developed. Transition probabilities for rele-
vant events were estimated based on RIKS-HIA, a register on
patients treated in the coronary care units at 74 (out of 78) hos-
pitals throughout Sweden. Patients were assumed to be treated
for one year with an effect based on the PCI-CURE trial. Costs
for the intervention and the deﬁned events were collected from
published sources and recalculated to 2003 prices. Life-years
gained were used as the measure of effectiveness, with QALYs
gained as a sensitivity analysis. The perspective was that of the
Swedish society with a separate analysis using a health care cost
perspective. Costs and effects were discounted at 3%. RESULTS:
The model predicts a net gain in survival of 0.04 years when
adding clopidogrel. This comes at a net increased cost of 441€
if only direct costs are included. Including indirect costs, the net
increase is reduced to 326€. The resulting cost-effectiveness ratio
was 10,782€ and 7971€ per life-year gained for the different def-
initions of cost. Assuming a 0.1 reduction in utility following a
MI, the cost per QALY gained was 6381€. Cost-effectiveness
ratios were even lower in diabetics compared to non-diabetics.
Results were robust to changes in discount rate and variations
in unit costs. CONCLUSIONS: The predicted cost-effectiveness
ratios are well below the threshold values generally considered
cost-effective. Adding clopidogrel to ASA thus appears cost-
effective in this indication.
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OBJECTIVES: High density lipoprotein-cholesterol (HDL-C) is
inversely and independently associated with increased risk of car-
diovascular disease (CVD). The importance of HDL-C as a risk
factor for CVD is well accepted. We performed a modelling study
to estimate the incremental cost per additional patient achieving
target HDL-C (≥1mmol/L) when Niaspan (extended release
niacin) is added to stable statin therapy in CVD patients from
the perspective of the National Health Service in the UK.
METHODS: A 3-step probabilistic model was developed. Step
1: population of 10,000 patients with a normal distribution of
lipid proﬁles deﬁned by mean and standard deviation was
created. Step 2: treatment effects of atorvastatin 10mg were
applied to the population and those whose low density lipopro-
tein-cholesterol (LDL-C) was satisfactory (£3.0mmol/L) but did
not reach target HDL-C (≥1.0mmol/L) received treatment with
Niaspan. Step 3: treatment effects of Niaspan were applied in
patients. Baseline lipid values and treatment effects were ran-
domly sampled from distributions drawn from published epi-
demiological and clinical studies using second order Monte
Carlo methodology. Cost for drugs and initiation of Niaspan
treatment were taken from published sources. Results were pre-
sented for the initiation year, taking into account initiation costs
and drop-outs, and maintenance year scenarios. RESULTS: In
total, 16.3% of patients required Niaspan in addition to ator-
vastatin treatment to control dyslipidemia. Of these patients,
29.4% and 36.7% reached target HDL-C after addition of
Niaspan in the initiation and maintenance years respectively.
Additional costs in Niaspan treated patients were £320.30 
and £252.30 for initiation and maintenance years respectively,
leading to incremental costs of £1089 and £687 per additional
patient achieving HDL-C target. CONCLUSIONS: The addi-
tional costs per patient treated to HDL-C target by adding
Niaspan to statin therapy are comparable to those reported in
the literature for treating patients with statins to LDL-C or total
cholesterol targets.
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OBJECTIVES: Little is known about the cost-effectiveness of
secondary prevention after percutaneous coronary intervention
(PCI). Aims of this study are to estimate 1) the cost-effectiveness
of routine ﬂuvastatin therapy after a ﬁrst successful PCI in The
Netherlands, and 2) the chance that ﬂuvastatin therapy is cost-
effective given a society’s willingness to pay as laid down in
Dutch guidelines. METHODS: A cost-effectiveness analysis was
performed using data from the Lescol Intervention Prevention
Study (LIPS). In the LIPS trial, patients with normal blood cho-
lesterol to moderate hypercholesterolemia who had undergone a
ﬁrst PCI were randomized to receive either ﬂuvastatin 40mg
twice-daily plus dietary counseling or dietary counseling alone.
A Markov model (DataPro) was used to estimate the incremen-
tal costs per quality-adjusted life year (QALY) and life year
gained (LYG). Costs were based on prices and reimbursed
charges, utility data were drawn from literature. Hospital costs
(admissions and procedures) were extracted from a database
with complete national coverage. 10,000 Monte Carlo simula-
tions and multivariate analysis were used to assess (2nd order)
uncertainty. RESULTS: The mean net incremental costs of
routine statin treatment were 734€ (SD: 686€) per patient over
10-years compared with controls. Treatment resulted in an incre-
mental 0.078 (0.047) QALYs or 0.082 LYG (0.041). The incre-
mental cost per QALY and LYG were 9312€ (14,648€) and
8954€ (16,617€) respectively. The sensitivity analysis revealed
that the cost of ﬂuvastatin and the discount rate had the largest
effect on the ICER. Anticipating a willingness to pay of 20,000€
per QALY, there is a 75.1% chance that ﬂuvastatin treatment is
cost-effective. CONCLUSIONS: Statin therapy with ﬂuvastatin
